Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $71.0 million.

  • Myriad Genetics' Other Operating Expenses fell 1.53% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $622.5 million, marking a year-over-year increase of 82.28%. This contributed to the annual value of $319.6 million for FY2024, which is 20.50% down from last year.
  • As of Q3 2025, Myriad Genetics' Other Operating Expenses stood at $71.0 million, which was down 81.73% from $388.6 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Other Operating Expenses peaked at $388.6 million during Q2 2025, and registered a low of $47.8 million during Q3 2021.
  • Its 3-year average for Other Operating Expenses is $113.7 million, with a median of $84.4 million in 2024.
  • In the last 5 years, Myriad Genetics' Other Operating Expenses plummeted by 37.62% in 2024 and then surged by 360.43% in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' Other Operating Expenses stood at $107.8 million in 2021, then rose by 15.86% to $124.9 million in 2022, then decreased by 7.45% to $115.6 million in 2023, then fell by 18.94% to $93.7 million in 2024, then decreased by 1.53% to $71.0 million in 2025.
  • Its Other Operating Expenses stands at $71.0 million for Q3 2025, versus $388.6 million for Q2 2025 and $69.2 million for Q1 2025.